CN1234409C - Combinaton of medication for treating depression and preparation method - Google Patents
Combinaton of medication for treating depression and preparation method Download PDFInfo
- Publication number
- CN1234409C CN1234409C CN200410034937.7A CN200410034937A CN1234409C CN 1234409 C CN1234409 C CN 1234409C CN 200410034937 A CN200410034937 A CN 200410034937A CN 1234409 C CN1234409 C CN 1234409C
- Authority
- CN
- China
- Prior art keywords
- ginger
- oil
- pachyman
- pharmaceutical composition
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 8
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 4
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 4
- 229960004853 betadex Drugs 0.000 claims abstract description 4
- 241000234314 Zingiber Species 0.000 claims description 16
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 16
- 235000008397 ginger Nutrition 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 208000020401 Depressive disease Diseases 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000010649 ginger oil Substances 0.000 abstract 2
- 238000002474 experimental method Methods 0.000 description 14
- 239000003921 oil Substances 0.000 description 11
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 239000000935 antidepressant agent Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 229940005513 antidepressants Drugs 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 235000014347 soups Nutrition 0.000 description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- 244000197580 Poria cocos Species 0.000 description 3
- 235000008599 Poria cocos Nutrition 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000010135 fructus aurantii immaturus Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 239000001169 1-methyl-4-propan-2-ylcyclohexa-1,4-diene Substances 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241000242759 Actiniaria Species 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011021 lapis lazuli Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007875 phellandrene derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 1
- 229930001895 zingiberene Natural products 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medicinal composition for treating depression, which is composed of two active components of the following dosage: 3.5 to 14g of pachyman and 0.2 to 3.5g of ginger oil. The preparation method has the step that after the ginger oil is contracted by beta-cyclodextrin according to the weight proportion, the medicinal composition of PG is obtained. The composition is used for preparing medicine for treating depression, and has the advantages of stabile curative effect, high safety and reliability, simple process, easy production, etc.
Description
Patent application of the present invention is denomination of invention the dividing an application for " antidepressant composition and preparation method thereof " (application number 02138217.4) patent by JIUYUE in 2002 application on the 5th.
One, technical field:
The present invention relates to the composition and method of making the same and the medicinal usage of active ingredient of natural plant, particularly relate to the medicine that the preparation of compositions of pachyman and oil of ginger is become the treatment depression.
Two, background technology:
Depression refers to the affective disorders syndrome, and low with mental state is principal character.Clinical depressed mood, feeling of fatigue, anhedonia, thinking and the motion sluggishness of mainly showing as is with anxiety, sleep disorder, inappetence, despair and the vain hope etc. of committing suiside.Depression is the able-bodied commonly encountered diseases of the harm whole mankind, frequently-occurring disease.According to World Health Organization's psychosis popularity investigation report, whole world depression prevalence is up to 3～5%, and major depression patient homicide rate is up to 15～18%, and lifelong attack rate is up to 8～12% (men), 20～25% (woman).Clinically, normal and other serious disease of depression such as heart disease, apoplexy, cancer, immune disease etc. and deposit.Relevant depression is EPDML to be studies show that: along with the quickening of worldwide social industrialization, urbanization process, stressors increases greatly in the social life, the depression prevalence is in continuous rising, and ill crowd enlarges day by day, and wherein the morbidity in elderly population will be more outstanding.Depression will become one of main disease that the 21 century mankind face.
The seriousness of depression fashion trend and patient have caused the extensive attention of countries in the world because of the decline of psychological diathesis due to the mental disorder and the infringement of social function.The demand of antagonism down increases day by day in the world wide, and this quasi drugs world market sales volume is with the speed increment in every year 16.2% in recent years.The development of the control of depression and antidepressant new drug has become one of current international the world of medicine forward position hot research problem.
Depression cause of disease complexity, closely related with Physiological Psychology, not clear and definite yet so far.May with for a long time stress be relevant with cerebrum 5-hydroxytriptamine (5-HT), norepinephrine monoamine neurotransmitter metabolism such as (NE) and functional disorder that emotion causes, by excessive activation SAM (sympathetic adrenal-medullary) system, HPA (hypothalamic-pituitary-adrenocortical) system, link behavior and physiological effect that mediation is relevant with hormonal system and immune system.
The Western medicine of clinical treatment depression has multiple at present.Oxidase inhibitor (MAO-AI) (as moclobemide) is to the maincenter monoamine neurotransmitter inhibitory action of having degraded; 5-hydroxy tryptamine reuptake inhibitor (SSRI) (fluoxetine), then selectivity suppresses the 5-HT reuptake; And plain reuptake inhibitor (SNRI) (as venlafaxine) optionally suppresses 5-HT and NE heavily absorbs on 5-hydroxy tryptamine-noradrenaline; Dual function not only suppresses the reuptake of 5-HT but also block postsynaptic 5-HT in the antidepressants (as nefazodone) of 5-hydroxy tryptamine link
2Receptor; NE and DA reuptake inhibitor (as bupropin) selectivity suppress NE and DA reuptake.These medicines are limit because of itself effect characteristic mostly, have that the antidepressant spectrum is narrower, toxic and side effects is big, price is high, an easy shortcoming such as recurrence after the drug withdrawal.
Traditional Chinese medical science melancholia refers to the class disease that feelings will is peaceful, depression and stagnation of QI causes, with the depression of doctor trained in Western medicine many common parts is arranged.Chinese medicine contains the various active composition, can regulate each system on the whole, reaches the effect that safety is cured.Herba Sidae Rhombifoliae soup (Radix Bupleuri, Radix Scutellariae (processed with wine), Radix Codonopsis, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Radix Glycyrrhizae, Rhizoma Zingiberis Recens, Fructus Jujubae), BANXIA HOUPU TANG (Rhizoma Pinelliae, Cortex Magnoliae Officinalis, Poria, Rhizoma Zingiberis Recens, Folium Perillae) and platinum diffusing (Alumen, Radix Curcumae, Rhizoma Anemones Altaicae, Zhu sand, artificial Calculus Bovis) treatment " globus hystericus ", depression, depressive psychosis have been reported successively; Hu Sirong is with forgetting melancholy soup (Magnetitum, Lapis Micae Aureus, Fructus Aurantii Immaturus, Cortex Phellodendri, the Rhizoma Pinelliae, Cortex Magnoliae Officinalis, Poria (processed with Cinnabaris), refreshing meat, Cortex Cinnamomi, Folium Perillae, Rhizoma Acori Graminei, Rhizoma Zingiberis Recens) treatment depression 470 examples according to one's conscience, and recovery from illness 70.2% takes a turn for the better 20.2%, total effective rate 90.4%; Zhao Zhisheng ' presses down and considers health ' the capsule for treating depression from intending Chinese medicine, and general curative effect is better than western medicine group; Human Shu Yu regulation of mental activities soup (Radix Bupleuri, Radix Curcumae, Rhizoma Acori Graminei, Fructus Aurantii Immaturus, Semen Persicae, Flos Carthami, Semen Platycladi, Radix Polygalae, DUANLONGMU, Radix Salviae Miltiorrhizae) such as Ma Yunzhi treatment apoplexy retarded depression disease, its cure rate is 39.06%, obvious effective rate is 30.40%, effective percentage is 21.09%, inefficiency is 9.45%, and obviously improves main and simultaneous phenomenon; The rugged wise man of Japan's tail finds that Xiao Jianzhong Tang (Ramulus Cinnamomi, Rhizoma Zingiberis Recens, Radix Paeoniae, Radix Glycyrrhizae, Fructus Jujubae, maltose end) has regulating action to depressive neurosis patient emotion; Research finds that also Radix Bupleuri adds Os Draconis Concha Ostreae soup (Radix Bupleuri, the Rhizoma Pinelliae, Ramulus Cinnamomi, Poria, Radix Scutellariae, Fructus Jujubae, Radix Ginseng, Concha Ostreae, Os Draconis, Rhizoma Zingiberis Recens) treatment effectiveness and shows fatigue, headache, nerve of plant symptom aspect there was no significant difference such as dizzy, stresses treatment depression, nervous.
The onset of above-mentioned Chinese medicine compound recipe is slow, and component more complicated, drug effect are remarkable inadequately, is difficult to formulate and implement the strict quality standard.
Poria is the dry sclerotia of Polyporaceae Poria cocos (Schw.) Wolf, and polysaccharide can account for the 80-93% of dry weight, is mainly β-pachyman etc." property of medicine opinion " record, Poria " appetizing, preventing or arresting vomiting is contrary, kind tranquilizing mind " has the effect of strengthening the spleen stomach function regulating, mind tranquilizing and the heart calming.Rhizoma Zingiberis Recens is the bright rhizome of Zingiberaceae Zingiber officinale Rosc, contains volatile oil 0.25-3.0%, and wherein main component is zingiberol, zingiberene, phellandrene, camphene etc." Treatise on Dietetic Therapy " record, Rhizoma Zingiberis Recens " non-return, it is unhappy to loose, appetizing gas ", pharmacological testing shows that pachyman has significant sedation and immunoloregulation function, and has antitumor action.6-zingiberene, 6-gingerol, 6-zingiberene alcohol are main component in the oil of ginger, have multiple effects such as central nervous system's inhibitory action and antioxidation, antitumor, antiinflammatory and protection gastric mucosa.
Three, summary of the invention:
1. goal of the invention
Purpose of the present invention is exactly in order to address the above problem, and a kind of composition and method of making the same that is prepared into by pachyman and two kinds of compositions of oil of ginger is provided, and the application in preparation treatment depression medicine.
2. technical scheme
Pharmaceutical composition of the present invention is characterized in that it is made up of the plant extract component of following weight proportion: pachyman 3.5-14g, oil of ginger 0.2-3.5g; The weight proportion of said extracted thing effective ingredient is pachyman 10.0g and oil of ginger 1.0g.
After each component is mixed can with the beta-schardinger dextrin-mixed in equal amounts, to increase the stability of compositions component.The consumption of beta-schardinger dextrin-also can change in proper range as the case may be.
Preparation of drug combination method of the present invention the steps include:
(1) Poria is behind water extraction, and adding 95% ethanol to concentration of alcohol in the concentrated solution is 50-80%, and the gained precipitation is pachyman;
(2) Rhizoma Zingiberis Recens supercritical CO
2Extraction, Petroleum ether extraction, vapor distillation or water boiling and extraction get oil of ginger;
(3) pachyman 3.5-14g, oil of ginger 0.2-3.5g promptly get compositions with mixing behind the beta-cyclodextrin inclusion compound oil of ginger.
In compositions, add an amount of adjuvant then, can be made into the oral formulations of tablet, granule or capsule.These dosage forms are to prepare according to those skilled in the art institute well-known process.The adjuvant that is used to make moulding processs such as tablet, granule, capsule is the auxiliary agent of using always, and for example starch, gelatin, arabic gum, Polyethylene Glycol etc. also have surfactant, lubricant, disintegrating agent, antiseptic, correctives, pigment etc. in addition.
3. beneficial effect
Advantage of the present invention is:
Resulting composition is formed succinct, and prescription is reasonable, and main active is clear and definite.The active component that extracts from two kinds of tuckahoes and Rhizoma Zingiberis Recens is formed the PG compositions by weight ratio.
(2) drug effect is remarkable, safe and reliable.Animal test results shows that said composition high and low dose group all can significantly reduce the absolute dead time of mice, shows that said composition has tangible antidepressant activity.
(3) technology is simple, is easy to suitability for industrialized production.From Poria and Rhizoma Zingiberis Recens, extract the method for active component simple and also only need by weight ratio component to be mixed when being prepared into compositions after can obtain, so preparation is simple, help industrial large-scale production.
Four, the specific embodiment:
The pharmaceutical composition of embodiment 1. treatment depressions
A kind of pharmaceutical composition for the treatment of depression is made up of pachyman 3.5-14g, oil of ginger 0.2-3.5g;
Embodiment 2 preparation of drug combination methods the steps include:
(1) get dry poria cocos sclerotium, with the water extraction of 10 times of volumes three times, merge extractive liquid,, adding 95% ethanol to concentration of alcohol after concentrating is 80%, and the gained precipitation is pachyman, and yield is 80.1%;
(2) get dry Rhizoma Zingiberis Recens, with conventional vapor extraction three times, yield is 1.0%.
(3) get pachyman 10g and oil of ginger 1g, behind the beta-cyclodextrin inclusion compound oil of ginger, mix promptly getting compositions PG.In above-mentioned composition PG, add an amount of starch, make tablet.
Embodiment 3 compositionss are to the influence of desperate model mice behavior
Animal model: experiment of mice forced swimming and mouse tail suspension swimming test
Animal: male mice in kunming, body weight 28 ± 2g, random packet.
Behind the gastric infusion 15 days, carry out behavioral experiment, measure the absolute dead time in the experiment of mice forced swimming and outstanding tail;
The compositions component sees Table 1 to mice forced swimming experiment and the exercising result that hangs the tail experiment.A minimizing that cardinal symptom is a motivational behavior of depression, forced swimming experiment and the struggle of hanging in the tail experiment are the motivational behaviors of animal, the absolute motionless absence of motivation state that then reflects animal passiveness in the experiment.Most of antidepressant drugs can increase the motivational behavior of animal subject, reduce the forced swimming experiment and hang absolute dead time in the tail experiment.Two dosage of positive drug fluoxetine height all can significantly reduce the absolute dead time of mice in the experiment of forced swimming and outstanding tail.The compositions high dose group all can significantly reduce the absolute dead time of mice in two experiments.The result shows that compositions has tangible antidepressant activity.
Table 1 compositions is to the influence of dead time in the desperate model of mice behavior (x ± s)
| Group | Dosage (mg/kg) | The absolute dead time (s) | |
| The forced swimming experiment | Outstanding tail experiment | ||
| Blank fluoxetine PG | - 10 20 460 230 | 124.2±3.5 70.1±1.5 *** 31.6±2.1 *** 101.4±3.5 68.7±2.7 *** | 88.4±2.0 43.0±1.2 *** 25.2±1.1 *** 70.1±0.9 60.4±1.3 ** |
*P＜0.05,
*P＜0.01,
* *Compare with matched group P＜0.001.
Claims (5)
1. pharmaceutical composition for the treatment of depression is characterized in that it is made up of the plant extract effective ingredient of following weight proportion:
Pachyman 3.5-14g, oil of ginger 0.2-3.5g.
2. pharmaceutical composition according to claim 1 is characterized in that the weight proportion of extract effective ingredient
For: pachyman 10g, oil of ginger 1.0g.
3. method for preparing the pharmaceutical composition of claim 1, its preparation methods steps is:
(1) Poria water extraction, gained extracting solution suitably concentrate, and adding 95% ethanol to extracting solution concentration of alcohol is 50-80%, and the gained precipitation is pachyman;
(2) Rhizoma Zingiberis Recens supercritical CO
2Extraction, Petroleum ether extraction, vapor extraction or water boiling and extraction promptly get oil of ginger;
(3), promptly get compositions with mixing behind the beta-cyclodextrin inclusion compound oil of ginger with pachyman 3.5-14g and oil of ginger 0.2-3.5g.
4. pharmaceutical composition according to claim 1 is characterized in that in compositions, adds an amount of adjuvant, can be made into tablet, the solid orally ingestible of granule and capsule with conventional preparation method.
5. the application of the described pharmaceutical composition of claim 1 in preparation treatment depression medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200410034937.7A CN1234409C (en) | 2002-09-05 | 2002-09-05 | Combinaton of medication for treating depression and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200410034937.7A CN1234409C (en) | 2002-09-05 | 2002-09-05 | Combinaton of medication for treating depression and preparation method |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN02138217.4A Division CN1283312C (en) | 2002-09-05 | 2002-09-05 | Antidepressant composition and preparing process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1539497A CN1539497A (en) | 2004-10-27 |
| CN1234409C true CN1234409C (en) | 2006-01-04 |
Family
ID=34352245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200410034937.7A Expired - Fee Related CN1234409C (en) | 2002-09-05 | 2002-09-05 | Combinaton of medication for treating depression and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1234409C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006072213A1 (en) * | 2005-01-03 | 2006-07-13 | Hong Kong Jockey Club Institute Of Chinese Medicine Limited | Anti-depression formulations |
| CN109315782A (en) * | 2017-08-01 | 2019-02-12 | 无限极（中国）有限公司 | It is a kind of to have effects that improve the composition of depressive anxiety and its application |
| CN115501215A (en) * | 2022-07-14 | 2022-12-23 | 山东第一医科大学(山东省医学科学院) | Medicine for treating depression |
-
2002
- 2002-09-05 CN CN200410034937.7A patent/CN1234409C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1539497A (en) | 2004-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Ethnopharmacological uses, phytochemistry, biological activities, and therapeutic applications of Alpinia oxyphylla Miquel: A review | |
| CN1283258C (en) | Medicine for preventing fibrous liver and preparing method thereof | |
| KR100532703B1 (en) | Composition comprising a crude drug complex for preventing and treating gastrointestinal dyskinetic disease | |
| US8623424B2 (en) | Traditional Chinese medicinal compositions for treating depression, formulation thereof, method for preparing the same thereof | |
| CN102008643B (en) | Mixture for treating panasthenia | |
| Tan et al. | Chinese materia medica used in medicinal diets | |
| CN101711847B (en) | Oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis | |
| CN114010751B (en) | Traditional Chinese medicine composition for preventing and treating cancer-induced fatigue | |
| CN101347557B (en) | Medicament composition for refreshment and intelligence development and preparation and use thereof | |
| Xia et al. | Neuroplasticity: a key player in the antidepressant action of chinese herbal medicine | |
| CN100387293C (en) | Medicine composition and preparing method | |
| CN1234409C (en) | Combinaton of medication for treating depression and preparation method | |
| CN1283312C (en) | Antidepressant composition and preparing process thereof | |
| CN103876137B (en) | There is the traditional Chinese medicine health care product of improving water flood function | |
| CN105641419A (en) | Traditional Chinese medicine composition for treating Yin deficiency type cough caused by lung cancer | |
| CN102008644B (en) | Drug for treating neurasthenia and application thereof | |
| CN1611232A (en) | Medicinal composition with main effect of antifatigue, radioresistance and melancholia-resistance and its preparing method | |
| CN103638336B (en) | Full rhizoma gastrodiae tablet | |
| CN103933339B (en) | A kind of application of Chinese medicine composition in the drug of preparation treatment depression | |
| CN1183946C (en) | Medicines for treating depression and preparation thereof | |
| CN105688070A (en) | Medicine composition for treating postpartum depression | |
| CN104107242B (en) | A kind of Chinese medicine composition for the treatment of hyperthyroidism and its production and use | |
| CN102824446B (en) | Medicinal composition with anti-fatigue effect as well as preparation method and application thereof | |
| CN102416147B (en) | Medicinal composition for treating mania of patients abstained from drugs | |
| CN104645245B (en) | A kind of preparation method for Menopause depression pharmaceutical preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060104 Termination date: 20110905 |